New hope for IBD: IL-23 drugs tested in chinese patients

NCT ID NCT07184138

Not yet recruiting Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will follow 178 Chinese adults with Crohn's disease or ulcerative colitis who are starting treatment with IL-23 inhibitors (guselkumab or risankizumab). Researchers will track how well the drugs control symptoms and heal the gut over 52 weeks, as well as any side effects. The goal is to see if these newer biologics work in real-world Chinese patients, where data is currently limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interleukin-23 inhibitors (IL-23i) – guselkumab and risankizumab
What this could lead to: If successful, this study could provide real-world evidence that IL-23 inhibitors are effective and safe for Chinese patients with Crohn's disease or ulcerative colitis, potentially improving treatment options.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also early-stage for Chinese populations, and some patients may not respond or may experience side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMATORY BOWEL DISEASE (CROHN'S AND ULCERATIVE COLITIS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.